Skip to main content
Isaac Francis Photo
Isaac Francis

Isaac Francis

GrafaFinance Journalist

Finance journalist at Grafa. Covers tech, crypto, and markets, making complex finance clear for all. Passionate about innovation and trends.

Articles by Isaac Francis

Grafa
Health

AstraZeneca gets priority review for bladder cancer drug

AstraZeneca (NASDAQ:AZN) received U.S. Food and Drug Administration Priority Review for its supplemental Biologics License Application for IMFINZI (durvalumab) combined with enfortumab vedotin in patients with muscle-invasive bladder cancer who are ineligible for or have declined cisplatin-based chemotherapy.

Read more: AstraZeneca gets priority review for bladder cancer drug